Heart failure & cardiomyopathies

Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure

J Am Coll CardiolPublished Randomised controlled trial

An erratum to this article was published (J Am Coll Cardiol, 25 Jun 2024 ↗)

Primary result · Urine concentrationResult — go to the resultEstimate 134 mmol/L 95% CI 39.28–229.12

Authors' conclusion

Physiological-adaptive water conservation eliminated the expected osmotic diuretic potential of dapagliflozin and thereby prevented a glucose-driven increase in urine volume of approximately 10 mL/kg/d · 75 kg = 750 mL/kg/d.

Study context

Population
Chronic HF, NYHA class I/II, reduced EF, SGLT2 inhibitor-naïve33 completed
Participants
15 vs 14
Comparison
Dapagliflozin vs placebo
  • Dapagliflozinn = 15
  • Placebon = 14reference
Primary endpoint
Change from baseline in urine osmolyte concentration
Methodological detailssingle-centre, double-blind, placebo-controlled
  • Single-centre
  • Double-blind
  • Placebo-controlled

Primary result

Urine concentration · 4 weeks (late)

Estimate

134 mmol/L

95% CI 39.28–229.12

P < 0.01

As reported in the abstract

Secondary outcomes

OutcomeMean difference (mL/kg/d) (95% CI)P value
Urine volumeDapagliflozinvs PlaceboEarly2.8 (−1.97 to 7.48)P = 0.25
Urine volumeDapagliflozinvs PlaceboLate0.9 (−3.83 to 5.62)P = 0.70
OutcomeEstimateP value
Urine glucose excretionDapagliflozin vs Placebo · early (within 48 h)3.3 mmol/kg/d (95% CI 2.51–4.04)P < 0.0001
Urine glucose excretionDapagliflozin vs Placebo · late (4 weeks)2.7 mmol/kg/d (95% CI 1.98–3.51)P < 0.0001
Serum copeptinDapagliflozin vs Placebo · early5.5 pmol/L (95% CI 0.45–10.5)P < 0.05
Serum copeptinDapagliflozin vs Placebo · late7.8 pmol/L (95% CI 2.77–12.81)P < 0.01
Free water clearanceDapagliflozin vs Placebo · early−9.1 mL/kg/d (95% CI −14 to −4.12)P < 0.001
Free water clearanceDapagliflozin vs Placebo · late−11.0 mL/kg/d (95% CI −15.94 to −6.07)P < 0.0001

Original publication

Water Conservation Overrides Osmotic Diuresis During SGLT2 Inhibition in Patients With Heart Failure. J Am Coll Cardiol. Published 16 April 2024. doi:10.1016/j.jacc.2024.02.020

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.